2005
DOI: 10.1016/j.bpa.2004.12.002
|View full text |Cite
|
Sign up to set email alerts
|

The pharmacokinetics of ropivacaine in hepatic and renal insufficiency

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
6
0

Year Published

2006
2006
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 31 publications
0
6
0
Order By: Relevance
“…It has been observed that some local anesthetics exhibit flip-flop pharmacokinetics following epidural administration, such as ropivacaine [130132]. For instance, ropivacaine 0.2% was continuously infused (5 ml/h) epidurally for 48 h postoperation in patients scheduled for major abdominal or urologic surgery [130].…”
Section: Drug Examplesmentioning
confidence: 99%
“…It has been observed that some local anesthetics exhibit flip-flop pharmacokinetics following epidural administration, such as ropivacaine [130132]. For instance, ropivacaine 0.2% was continuously infused (5 ml/h) epidurally for 48 h postoperation in patients scheduled for major abdominal or urologic surgery [130].…”
Section: Drug Examplesmentioning
confidence: 99%
“…After EP administration a constant increase in drug concentration occurred during the 48-h infusion period. The absorption rate constant from the site of administration could be lower than the elimination rate constant (0.35 h −1 ) [6]; indicating that absorption is the rate-limiting step in elimination of ropivacaine after EP administration [6]. After a CPCB, plasma concentrations of ropivacaine decreased from 1.5 to 6 h then increased until 48 h (end of infusion) (Fig.…”
Section: Clinical Trialmentioning
confidence: 96%
“…Other metabolites include 2-hydroxymethyl-ropivacaine and 4-hydroxyropivacaine. After intra-venous administration, an elimination half-life of about 2 h was reported [6]. Ropivacaine is extensively bound to plasma proteins (mainly to ␣ 1 -acid glycoprotein) with a free fraction around 6% [7].…”
Section: Introductionmentioning
confidence: 98%
“…Ropivacaine as a single shot local anesthetic can be considered safe in patients with liver and kidney disease. 8 In patients with chronic end-stage liver disease, peak plasma concentrations of ropivacaine after a single intravenous ropivacaine dose are similar to those in healthy subjects. 8 , 9 Additionally, uremic patients have significantly higher alpha-1-acid glycoprotein plasma concentrations than non-uremic patients, so the peak plasma concentrations of free ropivacaine (related to toxicity) are similar in both groups.…”
mentioning
confidence: 88%